Anti-Histone Antibodies - Explore the Science & Experts | ideXlab



Scan Science and Technology

Contact Leading Edge Experts & Companies

Anti-Histone Antibodies

The Experts below are selected from a list of 347991 Experts worldwide ranked by ideXlab platform

Anti-Histone Antibodies – Free Register to Access Experts & Abstracts

R Caputo – One of the best experts on this subject based on the ideXlab platform.

  • nitrendipine induced subacute cutaneous lupus erythematosus
    European Journal of Dermatology, 2003
    Co-Authors: Angelo V Marzano, Alessandro Borghi, Maurizio Mercogliano, Maura Facchetti, R Caputo

    Abstract:

    A 66-year-old man presented with widespread annular and bullous subacute cutaneous lupus erythematosus (SCLE), developed after starting treatment for hypertension with the calcium channel blocker nitrendipine. A few days after withdrawal of the drug, while cutaneous manifestations were improving, left hemiparesis occurred. Laboratory investigations showed, in addition to anti-Ro, anti-La and Anti-Histone Antibodies, the presence of lupus anticoagulant, anticardiolipin Antibodies, prolonged APTT and thrombocytopenia. On the basis of the spontaneous regression of the patient’s skin lesions after discontinuation of the drug, a possible relationship between nitrendipine intake, the clinical events and the biological findings is discussed.

    Free Register to Access Article

Angelo V Marzano – One of the best experts on this subject based on the ideXlab platform.

  • nitrendipine induced subacute cutaneous lupus erythematosus
    European Journal of Dermatology, 2003
    Co-Authors: Angelo V Marzano, Alessandro Borghi, Maurizio Mercogliano, Maura Facchetti, R Caputo

    Abstract:

    A 66-year-old man presented with widespread annular and bullous subacute cutaneous lupus erythematosus (SCLE), developed after starting treatment for hypertension with the calcium channel blocker nitrendipine. A few days after withdrawal of the drug, while cutaneous manifestations were improving, left hemiparesis occurred. Laboratory investigations showed, in addition to anti-Ro, anti-La and Anti-Histone Antibodies, the presence of lupus anticoagulant, anticardiolipin Antibodies, prolonged APTT and thrombocytopenia. On the basis of the spontaneous regression of the patient’s skin lesions after discontinuation of the drug, a possible relationship between nitrendipine intake, the clinical events and the biological findings is discussed.

    Free Register to Access Article

Giampiero Girolomoni – One of the best experts on this subject based on the ideXlab platform.

  • drug induced lupus erythematosus with emphasis on skin manifestations and the role of anti tnfα agents
    Journal Der Deutschen Dermatologischen Gesellschaft, 2012
    Co-Authors: Camilla Dalle Vedove, Jan C. Simon, Giampiero Girolomoni

    Abstract:

    Drug-induced lupus erythematosus (DILE) is a lupus-like syndrome temporally related to continuous drug exposure which resolves upon drug discontinuation. There are currently no standard diagnostic criteria for DILE. Findings include skin manifestations, arthritis, serositis, anti-nuclear and Anti-Histone Antibodies positivity. Similarly to idiopathic lupus erythematosus, DILE can be divided into systemic (SLE), subacute cutaneous (SCLE) and chronic cutaneous lupus (CCLE). Systemic DILE presents as a milder version of idiopathic SLE, and the drugs most frequently implicated are hydralazine, procainamide and quinidine. Anti-TNFα therapies are the latest class of medications found to be associated, although rarely, with a “lupus-like” syndrome, which is however clinically distinct from classical DILE. Drug-induced SCLE is the most common form of DILE. It is very similar to idiopathic SCLE in terms of clinical and serologic characteristics. The most commonly implicated drugs are antihypertensive drugs and terbinafine, but in recent years also proton pump inhibitors and chemotherapeutic agents have been associated. Drug-induced CCLE is very rare and usually caused by fluorouracil agents and NSAIDS, but some cases have induced by pantoprazole and anti-TNFα agents.

    Free Register to Access Article

  • Drug-induced lupus erythematosus
    Archives of Dermatological Research, 2009
    Co-Authors: Camilla Dalle Vedove, Micol Giglio, Donatella Schena, Giampiero Girolomoni

    Abstract:

    Drug-induced lupus erythematosus (DILE) is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation of the offending drug. There are currently no standard diagnostic criteria for DILE and the pathomechanisms are still unclear. Similarly to idiopathic lupus, DILE can be diveded into systemic (SLE), subacute cutaneous (SCLE) and chronic cutaneous lupus (CCLE). Systemic DILE is characterized by typical lupus-like symptoms including skin signs, usually mild systemic involvement and a typical laboratory profile with positive antinuclear and Anti-Histone Antibodies, while anti-double strand (ds) DNA and anti-extractable nuclear antigens Antibodies are rare. High risk drugs include hydralazine, procainamide and isoniazid. Drug-induced SCLE is very similar to idiopathic SCLE in terms of clinical and serologic characteristic, and it is more common than the systemic form of DILE. Drugs associated with SCLE include calcium channel blockers, angiotensin-converting enzyme inhibitors, interferons, thiazide diuretics and terbinafine. Drug-induced CCLE is very rarely reported in the literature and usually refers to fluorouracile agents or non steroidal anti-inflammatory drugs. Recently, cases of DILE have been reported with anti-TNFα agents. These cases present with disparate clinical features including arthritis/arthralgia, skin rash, serositis, cytopenia and variable laboratory abnormalities. DILE to anti-TNFα agents differs in several ways to classic DILE. The incidence of rashes is higher compared to classical systemic DILE. In most cases of classic DILE visceral involvement is rare, whereas several cases of anti-TNFα DILE with evidence of renal disease have been reported. Low serum complement levels as well as anti-extractable nuclear antigen Antibodies and anti-dsDNA Antibodies are rarely present in classic DILE, whereas they are reported in half the cases of anti-TNFα DILE; in contrast, Anti-Histone Antibodies are described in classic DILE more often than in anti-TNFα DILE. Recognition of DILE in patients receiving anti-TNFα therapy can be difficult due to the symptoms of their underlying disease. A temporal association (months to years) of the offending drug with characteristic or suggestive symptoms, and resolution of symptoms on drug withdrawal is the best evidence for this diagnosis of DILE.

    Free Register to Access Article